Assert-IQ vs Reveal LINQ
AI Verdict
Choose Assert-IQ if…
Choose Assert-IQ if your institution requires an insertable cardiac monitor for exceptionally long-term monitoring, up to six years, to capture rare or infrequent arrhythmias. This system is also ideal for health systems prioritizing a robust, cloud-based data platform with proactive clinician alerts and comprehensive remote monitoring capabilities for extensive patient management.
View Assert-IQ →Choose Reveal LINQ if…
Choose Reveal LINQ if minimizing device size and ensuring future MRI compatibility (1.5T and 3T) are critical considerations for your patients. This tool is particularly well-suited for practices seeking AI-powered algorithms to reduce false alerts and streamline diagnostic workflows, coupled with a simplified insertion procedure.
View Reveal LINQ →When choosing between the Assert-IQ™ Insertable Cardiac Monitor (ICM) system from Abbott Medical and the Reveal LINQ from Medtronic, physicians should consider their specific needs for monitoring duration and AI-driven arrhythmia detection. Both are minimally invasive, implantable devices designed for long-term, continuous cardiac monitoring to diagnose and manage heart rhythm disorders.
The Assert-IQ™ system excels in providing extended monitoring, offering up to six years of continuous data collection, which is ideal for patients requiring very long-term observation. Its advanced arrhythmia detection algorithms and proactive clinician alerts are designed for comprehensive arrhythmia detection. In contrast, the Reveal LINQ, while smaller, provides continuous ECG monitoring for up to three years. A key practical difference lies in their AI capabilities: Reveal LINQ specifically highlights its AccuRhythm™ AI algorithms for reducing false alerts, particularly for atrial fibrillation and pauses, potentially minimizing alert fatigue for clinicians. It also offers MRI conditional compatibility without a post-insertion waiting period.
Therefore, a physician prioritizing the longest possible monitoring duration and a broad spectrum of advanced arrhythmia detection might lean towards Assert-IQ™. Conversely, a physician who values a smaller device, a slightly shorter but still substantial monitoring period, and AI algorithms specifically tuned to reduce false positives for common arrhythmias, along with immediate MRI compatibility, may find the Reveal LINQ to be a more suitable choice.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Assert-IQ | Reveal LINQ |
|---|---|---|
| Pricing | Enterprise | Contact vendor for pricing |
| Deployment | Hybrid | Implantable medical device with a bedside patient monitor (MyCareLink™) for data transmission and a mobile app (Reveal LINQ™ Mobile Manager) for clinicians. |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Reveal LINQTool B (Reveal LINQ) explicitly offers a 'Reveal LINQu2122 Mobile Manager' app for clinicians, providing convenient device management. While Tool A (Assert-IQ) mentions remote monitoring and a patient activator, it lacks a dedicated mobile app for clinicians, which is a significant usability advantage for managing patient data and device settings on the go.
Clinical Value
Reveal LINQWhile Tool A (Assert-IQ) offers a longer monitoring duration (up to 6 years), Tool B (Reveal LINQ) highlights specific AI-driven advantages with its 'AccuRhythmu2122 AI algorithms for reduced false alerts (AF and pause)'. This directly addresses a critical clinical challenge by improving diagnostic accuracy and reducing clinician burden. Additionally, Tool B's MRI Conditional feature without post-insertion waiting offers a significant practical benefit for patient care and imaging flexibility.
Pricing & Value
TieBoth tools follow a non-transparent, enterprise-level pricing model that requires direct contact with the vendor for institutional quotes. Neither offers a free trial. Without public pricing details or specific value-based purchasing information, it is impossible to definitively compare their pricing or overall value proposition.
Enterprise Readiness
TieBoth tools are FDA-cleared and HIPAA-compliant, indicating they meet essential regulatory requirements for healthcare enterprises. They are developed by major medical device companies (Abbott and Medtronic) and target large health systems, hospitals, and cardiology clinics. While Tool A explicitly states data export capabilities, Tool B's integrated CareLinku2122 network and clinician mobile app also suggest robust enterprise data management and workflow integration.
Innovation
Reveal LINQTool B (Reveal LINQ) demonstrates more distinct innovations, including being the 'world's smallest' insertable cardiac monitor and leveraging 'AccuRhythmu2122 AI algorithms for reduced false alerts'. Its MRI Conditional feature without a post-insertion waiting period also represents a significant advancement in patient convenience and safety. While Tool A's 6-year monitoring duration is impressive, Tool B's innovations address multiple aspects of device design, AI accuracy, and patient experience.
Support & Docs
TieBoth Assert-IQ and Reveal LINQ are products from highly reputable and established medical device manufacturers, Abbott Medical and Medtronic, respectively. These companies are known for providing comprehensive support, training, and extensive documentation for their complex medical devices to healthcare professionals. Without specific comparative data on their support structures, it is not possible to distinguish between them.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Assert-IQ | Reveal LINQ |
|---|---|---|
| Name | Assert-IQ | Reveal LINQ |
| Company | Abbott Medical | Medtronic |
| Description | The Assert-IQu2122 Insertable Cardiac Monitor (ICM) system provides long-term, continuous monitoring and advanced arrhythmia detection to aid physicians in diagnosing and managing patients with suspected heart rhythm disorders. | Medtronic Reveal LINQ is a tiny, implantable cardiac monitor that continuously records ECG for up to three years, utilizing AccuRhythmu2122 AI algorithms to accurately detect and diagnose cardiac arrhythmias, including atrial fibrillation, cryptogenic stroke, and unexplained syncope. |
| Monitoring Duration | Up to 6 years | Up to three years |
| AI Algorithms | Advanced arrhythmia detection algorithms | AccuRhythmu2122 AI algorithms for reduced false alerts (AF and pause) |
| Mobile App | None | Reveal LINQu2122 Mobile Manager app for clinician device management |
| Key Features (Selected) | Long-term continuous cardiac monitoring (up to 6 years), Advanced arrhythmia detection algorithms, Remote monitoring capabilities | World's smallest insertable cardiac monitor (1.2 mL), Continuous ECG monitoring for up to three years, AccuRhythmu2122 AI algorithms for reduced false alerts (AF and pause) |
Videos
Demos, reviews, and walkthroughs featuring Assert-IQ and Reveal LINQ.